CN115887321A - Hibiscus manihot extract with allergy relieving effect and application thereof - Google Patents
Hibiscus manihot extract with allergy relieving effect and application thereof Download PDFInfo
- Publication number
- CN115887321A CN115887321A CN202211468125.8A CN202211468125A CN115887321A CN 115887321 A CN115887321 A CN 115887321A CN 202211468125 A CN202211468125 A CN 202211468125A CN 115887321 A CN115887321 A CN 115887321A
- Authority
- CN
- China
- Prior art keywords
- hibiscus
- extract
- allergy
- relieving
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 55
- 239000000284 extract Substances 0.000 title claims abstract description 39
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 35
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 35
- 230000007815 allergy Effects 0.000 title claims abstract description 28
- 240000005959 Abelmoschus manihot Species 0.000 title claims description 9
- 235000001642 Hibiscus manihot Nutrition 0.000 title claims description 9
- 244000048199 Hibiscus mutabilis Species 0.000 claims abstract description 52
- 235000003973 Hibiscus mutabilis Nutrition 0.000 claims abstract description 51
- 239000002537 cosmetic Substances 0.000 claims abstract description 46
- 239000003208 petroleum Substances 0.000 claims abstract description 34
- 235000013305 food Nutrition 0.000 claims abstract description 24
- 239000000126 substance Substances 0.000 claims abstract description 13
- 201000004624 Dermatitis Diseases 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000002031 ethanolic fraction Substances 0.000 claims description 5
- 239000000344 soap Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- PGLIUCLTXOYQMV-UHFFFAOYSA-N Cetirizine hydrochloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-UHFFFAOYSA-N 0.000 claims description 2
- 239000013040 bath agent Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- 229940100615 topical ointment Drugs 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 49
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract description 41
- 125000001033 ether group Chemical group 0.000 abstract description 18
- 230000002757 inflammatory effect Effects 0.000 abstract description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 8
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 29
- 235000005206 Hibiscus Nutrition 0.000 description 28
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 235000019441 ethanol Nutrition 0.000 description 18
- -1 coumarin, triterpenes Chemical class 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 235000013376 functional food Nutrition 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000219071 Malvaceae Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 244000130592 Hibiscus syriacus Species 0.000 description 1
- 235000018081 Hibiscus syriacus Nutrition 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 240000003243 Thuja occidentalis Species 0.000 description 1
- 235000008109 Thuja occidentalis Nutrition 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940069826 chlorella vulgaris extract Drugs 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 231100000739 chronic poisoning Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
Abstract
The invention discloses a cotton rose hibiscus extract with a allergy relieving effect and application thereof. The hibiscus mutabilis extract can be added into cosmetics, foods and substances for reducing the content of TNF-alpha inflammatory factors, and enables the cosmetics, the foods and the substances for reducing the content of the TNF-alpha inflammatory factors to have obvious allergy relieving effects, so that petroleum ether parts, ethanol parts and ethyl acetate parts are worth popularizing and using in the aspect of allergy relieving.
Description
Technical Field
The invention relates to the technical field of extraction of traditional Chinese medicine extracts, and particularly relates to a cotton rose hibiscus extract with a allergy relieving effect and application thereof.
Background
About 9000 kinds of cosmetic raw materials are used at present, and in addition to some raw materials having certain toxicity and irritation, new toxic substances may be generated in the process of processing. In addition, a considerable amount of auxiliary materials such as preservatives, spices, surfactants and the like are added, and although the performance and the application of the cosmetics are improved, the addition of the auxiliary materials also provides an environment for the growth of microorganisms, increases the toxic and side effects of the cosmetics, and can cause dermatitis, allergy, acute and chronic poisoning, infection caused by microorganisms and the like. It is therefore of great importance that the correct use of cosmetic raw materials avoids the occurrence of the corresponding side effects.
The traditional Chinese medicine cosmetic is prepared from pure traditional Chinese medicines or is prepared by adding traditional Chinese medicines or traditional Chinese medicine active ingredients into a chemical compound matrix, and is more and more popular with consumers all over the world due to the characteristics of greenness, naturalness, safety, reliability and the like under the guidance of the traditional Chinese medicine theory, but is not natural or safe. Some herbal extracts have been shown to have low skin irritation, phototoxicity, and cumulative toxicity, such as nephrotoxicity, hepatotoxicity, neurotoxicity, carcinogenesis, teratogenicity, mutagenic toxicity, reproductive toxicity, etc. Therefore, the selection of traditional Chinese medicinal materials in the cosmetics has great influence on the safety of the cosmetics. The selection of proper Chinese medicinal material types and components is particularly important for exerting the efficacy and ensuring the safety of the Chinese medicinal materials.
Although the selection of the traditional Chinese medicinal materials is very important, the method for extracting the effective components in the traditional Chinese medicinal materials is more important, and different methods are adopted, so that the content difference of the effective components is very large, and the content of toxic substances is different from the natural level, so that the method for extracting the effective components in the traditional Chinese medicinal materials is particularly important.
Skin allergy is a common skin disease, and medicines are required to relieve and treat allergic symptoms such as pruritus, desquamation, red swelling and the like. Inflammatory factors and pro-inflammatory mediators, such as TNF- α, IL-6, iNOS, and COX-2, can induce or exacerbate the development of skin allergy. Therefore, the content of related inflammatory factors is inhibited, and the skin allergy symptoms can be relieved, and even the inflammation is avoided. At present, cosmetics mainly having the effects of relieving allergy and soothing skin are oriented to the market, but the types of the cosmetics are few, and the cosmetics are different in quality.
Hibiscus mutabilis L is a hibiscus plant of Malvaceae, and its dry leaves are used in pharmacopoeia, and its main functions are cooling blood, detoxicating, detumescence and relieving pain. It is indicated for abscess, deep-rooted carbuncle, swelling of body, wound with snake-Dan, scald, conjunctival congestion, swelling and pain, and traumatic injury. It is said from Ben Cao gang mu that it is used to treat all large and small carbuncle, abscess and malignant boil, subdue swelling, expel pus and alleviate pain. Modern medical research shows that the cotton rose hibiscus contains chemical components such as flavone, organic acid, volatile components, stigmasta, anthraquinone, coumarin, triterpenes, lignans and inorganic elements and has wide pharmacological effects of resisting nonspecific inflammation, nephropathy, hepatopathy, diabetes, bacteria, virus, immunoregulation, tumor, parasite and the like. However, the research on cotton rose leaves at present mainly focuses on the aspects of extraction of effective components and oxidation activity research, and few researches on cotton rose parts with allergy relieving efficacy are conducted.
Disclosure of Invention
The invention aims to provide a cotton rose hibiscus extract with a allergy relieving effect and application thereof, and aims to solve the problem that cotton rose hibiscus parts corresponding to the allergy relieving effect are rarely researched.
The first purpose of the invention is to provide a cotton rose hibiscus extract with a allergy relieving effect, wherein the cotton rose hibiscus extract is derived from at least one of petroleum ether parts, ethanol parts and ethyl acetate parts of cotton rose hibiscus.
The second purpose of the invention is to provide a skin care cosmetic, which contains the cotton rose hibiscus extract, preferably, the content of the cotton rose hibiscus extract is 0.05-20 wt%, for example: 3wt%,8wt%,10wt%,12wt%, 15wt%, 18wt%, etc., more preferably, 0.2 to 1wt%, for example: 0.5wt% and 0.8wt%.
The third purpose of the invention is to provide a skin allergy-relieving food, which contains the hibiscus mutabilis extract, preferably, the content of the hibiscus mutabilis extract is 0.05-20 wt%, for example: 3wt%,8wt%,10wt%,12wt%, 15wt%, 18wt%, etc., more preferably, 0.2 to 1wt%, for example: 0.5wt% and 0.8wt%.
The fourth purpose of the invention is to provide the application of the hibiscus mutabilis extract in a substance for reducing the content of TNF-alpha.
The inventor of the invention finds that aiming at the treatment of skin allergy diseases, the types of cosmetics are few and the effects are different, so that the extract of the cotton rose is adopted to relieve allergy, but at present, no report is made about the positions of the cotton rose aiming at the allergy relieving part, and the antioxidant activity of the cotton rose extract obtained by various extraction methods is only researched, so that the inventor of the invention researches various extraction methods with the aim of screening the positions of the cotton rose with obvious allergy relieving effect to finally obtain the cotton rose parts with obvious allergy relieving effect.
Because the traditional Chinese medicine has the characteristics of multiple components, multiple targets and multiple ways, specific components or parts of the traditional Chinese medicine are separated and purified, other ineffective, ineffective or toxic components can be effectively removed, and the effective components are concentrated, so that the quality of the traditional Chinese medicine is very important to improve. Generally, traditional Chinese medicines often contain various compounds such as alkaloids, terpenoids, steroids, saccharides and the like, and traditional Chinese medicine components and parts are usually extracted by methods such as a water solvent, an alcohol solvent and the like. Therefore, the method, the components and the parts are determined, which is helpful for clarifying the specific efficacy and the safety of the traditional Chinese medicine.
As used herein, "cotton rose," also known as hibiscus flower, antifrost flower, lotus, cotton rose, 26489mu, trifoliate flower, jiu flower, tien Gosssan, rough flower, cooling paste, etc., is malvaceae, shrubalthea deciduous shrub or arborvitae. Flowers are singly born between the axilla of the branch end and the leaf. Both flowers and leaves can be used as herbs, and they have the actions of clearing heat and removing toxicity, relieving swelling and draining pus, cooling blood and stopping bleeding.
In the present invention, the extract of hibiscus mutabilis can be extracted from natural, hybrid or variant plants thereof, or can be extracted from plant tissue cultures.
Compared with other preparation methods, the hibiscus manihot extract obtained by the method has obvious allergy relieving effect, which indicates that the hibiscus manihot extract is at least one of a petroleum ether part, an ethanol part and an ethyl acetate part, and preferably the petroleum ether part and/or the ethyl acetate part.
As used herein, the term "petroleum ether fraction", ethanol fraction "and" ethyl acetate fraction "refer to hibiscus extract having a pronounced allergy-relieving effect obtained by treating hibiscus extract with a corresponding solvent.
The part can be prepared by the following steps: firstly, extracting the powder of cotton rose leaves by adopting alcohol substances with certain concentration, or simultaneously extracting by ultrasound or microwave, then removing the alcohol substances, and finally extracting by adopting petroleum ether, ethanol or ethyl acetate.
The part can be added into cosmetics or food.
The cosmetic added to the cosmetic may be in a form selected from the group consisting of a solution, a topical ointment, a cream, a foam, a nourishing lotion, a moisturizing lotion, a pack, a softening lotion, an emulsion, a barrier cream, a essence, a soap, a liquid cleanser, a bath agent, a sunscreen cream, a sunscreen oil, a suspension, an emulsion, a paste, a gel, a cream, a powder, a soap, a surfactant-containing facial cleanser, an oil, a powder foundation, an emulsion foundation, a cream foundation, a patch, and a spray, but is not limited thereto.
In addition, the skin allergy-relieving cosmetic of the present invention may further comprise one or more cosmetically acceptable carriers formulated into one or more of general skin cosmetics, and as usual ingredients, for example, oils, water, surfactants, skin allergy-relieving agents, lower alcohols, thickeners, chelating agents, pigments, preservatives, perfumes, and the like may be appropriately formulated, but not limited thereto.
In the present invention, the cosmetically acceptable carrier contained in the skin allergy-relieving cosmetic is various depending on the formulation.
When the dosage form of the present invention is an ointment, paste, cream or gel, as a carrier ingredient, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or a mixture thereof may be used.
When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof can be used as a carrier component, and when the formulation is a spray in particular, a propellant such as chlorofluorocarbon, propane/butane, or dimethyl ether may be further contained.
When the dosage form of the present invention is a solution or emulsion, as a carrier ingredient, a solvent, solubilizer or emulsifier may be used, and for example, water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylene glycol oil, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol fatty acid esters, polyethylene glycol or fatty acid esters of sorbitan may be used.
When the dosage form of the present invention is a suspension, as a carrier ingredient, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitol ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, or the like can be used.
When the formulation of the present invention is a soap, as a carrier ingredient, alkali metal salts of fatty acids, fatty acid half-ester salts, fatty acid protein hydrolysates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerin, sugars, and the like may be used.
The present invention provides a skin allergy-relieving food containing at least one of the petroleum ether site, the ethanol site and the ethyl acetate site as an active ingredient. The food may be used in the form of a health functional food, but is not limited thereto. In addition, the composition may contain a food additive acceptable in terms of food science in addition to the effective ingredient.
In the present invention, the "food additive" refers to a component that can be added to a food as an aid, and is an additive to be added when preparing a functional health food in various forms, and can be appropriately selected and used by those skilled in the art. As examples of the food additive, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavors, coloring agents, fillers, pectins and salts thereof, alginic acids and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like are contained, but the type of the food additive of the present invention is not limited by the above examples.
The food of the present invention may contain a health functional food. In the present invention, the "health functional food" refers to a food prepared or processed into a form of tablet, capsule, powder, granule, liquid, pill, etc. using a raw material or an ingredient useful for a human body. Here, "functionality" means an effect of regulating nutrients or physiological actions and the like for the structure and function of the human body to be beneficial for health. The health functional food of the present invention can be prepared by a method generally used in the art, and during the preparation, raw materials and ingredients generally added in the art may be added.
The formulation of the health functional food may be prepared without limitation as long as it is a known formulation of a health functional food. The food of the present invention can be prepared in various forms, is different from ordinary drugs, has the advantage of no side effect when the food is taken as a raw material for a long time, has good portability, and can be taken as a supplement for improving the skin allergy-relieving effect.
The health functional food of the present invention may take a form without limitation, may contain food in a conventional sense, and may be mixed with terms known in the art, such as functional food. In addition, the health functional food of the present invention is prepared by mixing appropriate other auxiliary ingredients and known additives that may be contained in the food according to the selection of those skilled in the art. Examples of foods that can be added include meats, sausages, breads, chocolates, confectioneries, snacks, cookies, pizza, instant noodles, other noodles, chewing gums, milk products containing ice cream, various soups, beverages, teas, tonics, alcoholic beverages, vitamin compounds, and the like. In addition, it contains food used as animal feed.
In addition, the present invention provides a pharmaceutical external product for skin allergy relief, which contains at least one of a petroleum ether fraction, an ethanol fraction and an ethyl acetate fraction as an active ingredient.
The pharmaceutical external product of the present invention may further contain a pharmaceutically acceptable carrier, excipient or diluent as necessary, in addition to the above-mentioned components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not affect the effect of the present invention, and may include, for example, a filler, a bulking agent, a binder, a wetting agent, a disintegrant, a surfactant, a lubricant, a sweetener, a perfume, a preservative, and the like.
As representative examples of the pharmaceutically acceptable carrier, excipient or diluent of the present invention, there are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, gum arabic, alginate, calcium phosphate, calcium carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable ester, witepsol, polyethylene glycol (Macrogol), tween 61, cacao butter, lauric acid and the like.
In addition, in the case where at least one of the petroleum ether moiety, the ethanol moiety and the ethyl acetate moiety of the present invention is used as a pharmaceutical preparation for external use, it may further contain one or more active ingredients exhibiting the same or similar functions. For example, known soothing ingredients may be included. When additional soothing ingredients are included, the soothing effect of the composition of the present invention may be further enhanced. When the above components are contained, skin safety, ease of preparation, and stability of the active ingredient due to combined use can be considered. The pharmaceutical external composition may include one or more ingredients selected from the group consisting of retinoic acid, TGF, proteins derived from animal placenta, betulinic acid, chlorella vulgaris extract and derivatives thereof, and various plant extracts, as a soothing ingredient known in the art. The content of the additional component is 0.001 to 10wt% based on the total weight of the composition, and the content range can be adjusted according to conditions such as skin stability and easiness of formulation of the hibiscus petroleum ether site of the present invention.
Examples of the external pharmaceutical preparations of the present invention include, but are not limited to, disinfecting detergents, shower foams, ointment solutions, wet tissues, coating agents, and the like, and the method of formulating the external pharmaceutical preparations, the amount of use, the method of use, the components, and the like can be appropriately selected from conventional techniques known in the art.
In addition, the petroleum ether site, ethanol site and ethyl acetate site of the present invention may be used in a skin soothing method comprising the step of applying to the skin of a subject. The subject can contain, without limitation, a mammal, including, for example, a mouse, livestock, human, and the like.
The invention provides a method for adding at least one of the petroleum ether part, the ethanol part and the ethyl acetate part into a substance for reducing the content of TNF-alpha, which can obviously reduce the content of TNF-alpha, thereby achieving the effect of relieving allergy.
The substance for reducing the content of TNF-alpha may contain the same components as those of the cosmetic and the food in addition to at least one of the petroleum ether site, the ethanol site and the ethyl acetate site, and thus the details thereof are not repeated.
The invention has the following beneficial effects:
1. the invention breaks through the research that the prior art is basically limited to how to extract the cotton rose hibiscus and the antioxidant activity of the extracted cotton rose hibiscus, and does not relate to the research on the specific effective part corresponding to the allergy-relieving effect of the cotton rose hibiscus, namely does not relate to the mode of extraction, and the cotton rose hibiscus extracting solution has good allergy-relieving effect. The method provided by the invention is used for searching for the extraction mode of the cotton rose hibiscus (namely which extraction part of the cotton rose hibiscus) from the allergy relieving effect to achieve a corresponding effect.
2. The hibiscus extract obtained by extracting the petroleum ether part, the ethanol part and the ethyl acetate part of the hibiscus has good allergy relieving effect, and particularly can obviously reduce the content of TNF-alpha, thereby achieving the allergy relieving effect.
3. The petroleum ether part, the ethanol part and the ethyl acetate part of the cotton rose have good allergy relieving effect, and compared with other existing extraction methods (using n-butyl alcohol as an extraction solvent), the effect of the extract is obviously better than that of the extracts obtained by other extraction methods.
4. The petroleum ether part, the ethanol part and the ethyl acetate part of the cotton rose have good allergy relieving effect and no side effect under a certain concentration, so the cotton rose can be used in cosmetics and medical drugs, and the cotton rose can be taken widely in practical application, and is worthy of popularization and application.
Drawings
FIG. 1 is a graph showing the results of the effect of example 1 (petroleum ether site) on cell activity;
FIG. 2 is a graph showing the results of example 2 (ethyl acetate site) on the effect on cell activity;
FIG. 3 is a graph showing the results of the effect of example 3 (ethanol site) on cell activity;
FIG. 4 is a graph of the effect of the sites of examples 1-3 and comparative example 1 and a control experiment on TNF- α;
FIG. 5 is a graph showing the effect of the sites of examples 1 to 3 and comparative example 1 and a control experiment on iNOS;
FIG. 6 is a graph of the effect of the sites of examples 1-3 and comparative example 1 and a control experiment on IL-6;
FIG. 7 is a graph of the effect of the sites of examples 1-3 and comparative example 1 and a control experiment on COX-2;
FIG. 8 is a graph of the effect of the cosmetic agents shown in Table 1 on TNF- α;
FIG. 9 is a statistical chart of the antiallergic test of the cosmetics shown in Table 1.
Detailed Description
In order to make the technical problems, technical solutions and advantageous effects to be solved by the present invention more apparent, the present invention is described in further detail below. It should be understood that the specific embodiments described herein are merely illustrative of the invention and do not limit the invention.
Example 1
Preparation of flos Hibisci Mutabilis petroleum ether part (flos Hibisci Mutabilis extract with obvious allergy relieving effect)
Taking a proper amount of cotton rose hibiscus leaf coarse powder, adding 10 times of 70% ethanol, performing reflux extraction for 2 times, namely 2 hours and 1.5 hours respectively, filtering, combining filtrates, concentrating until no alcohol smell exists, adding 100ml of water to obtain a suspension, performing extraction by using petroleum ether, performing continuous extraction for 3 times, combining the extract liquid obtained by each extraction, performing reduced pressure concentration and drying sequentially to obtain the petroleum ether fraction.
Example 2
This comparative example differs from example 1 in that: and extracting by using ethyl acetate with the same volume to obtain an ethyl acetate part.
Example 3
This comparative example differs from example 1 in that: extracting with ethanol of the same volume to obtain ethanol fraction.
Comparative example 1
This comparative example differs from example 1 in that: extracting with n-butanol of the same volume to obtain n-butanol fraction.
Experiment 1
Cell viability assay was performed on the extracted fractions obtained in examples 1-3
The experimental method is as follows:
(1) taking out the frozen RAW264.7 cells, and unfreezing the cells at 37 ℃ in a constant-temperature water bath kettle;
(2) diluting, centrifuging and beating the unfrozen cells, adding the cells into a culture dish, and then culturing in a constant-temperature constant-oxygen incubator;
(3) preparation of 5X 10 cells at log phase of growth 4 cell·mL -1 Adding the cell suspension with the concentration into a 96-well plate, and continuously culturing for 24 hours;
(4) samples of the sites obtained in examples 1 to 3 and comparative example 1 were prepared, and added to 96-well plates to give concentrations of 25, 50, 100, 200, 400. Mu.g.mL -1 Continuously culturing for 48 hours;
(5) each well was washed 3 times with PBS, the medium to which cck-8 reagent was added to a 96-well plate, culturing was continued for 30min, and then cell activity was measured.
The analysis software was SPSS version 22.0. Data are all expressed using mean ± sd. Significance was expressed as P <0.05, P <0.01. The results of the effect of the site on the cell activity in example 1 are shown in FIG. 1, and the results of the effect of the site in examples 2 and 2 on the cell activity are shown in FIGS. 2 and 3, respectively.
As can be seen from a comparison of FIGS. 1-3, all sample concentrations at the ethanol site (example 3) had no significant effect on cell viability. Further experiments showed that the concentration of the petroleum ether fraction (example 1) and ethyl acetate fraction (example 2) extract was not more than 200. Mu.g.mL -1 There was no statistically significant difference in the time, and there was no significant effect on the cell viability, indicating that the cell viability was not greater than 200. Mu.g.mL -1 When the concentration is within the range, the in vitro experiment can not cause obvious damage to cells, so that the subsequent inflammatory factor determination experiment adopts 200 mu g/mL -1 The sample concentration is used for carrying out experiments, and guiding opinions are also provided for the practical addition of the sample to foods and cosmetics.
Measurement of the level of inflammatory factor in the site obtained in examples 1 to 3 and comparative example 1 by Q-PCR
The experimental method comprises the following steps:
(1) petroleum ether extracts were precisely weighed (examples)1) Appropriate amounts of ethyl acetate extract (example 2) and ethanol extract (comparative example 2) were dissolved in DMSO to prepare a test solution for use. The final cell experiment administration concentration is 200 mug. Multidot.mL -1 ；
(2) RAW264.7 cells were cultured and added to a 96-well plate to give an initial concentration of 5X 10 4 cell·mL -1 Culturing for 24 hours;
(3) changing the culture medium, administering, continuously culturing for 48 hours, collecting cell supernatant of RAW264.7, extracting RNA, and identifying the concentration and purity of total RNA;
(4) the q-PCR technology is utilized to carry out the design and synthesis of experimental primers and the operation of reverse transcription of mRNA into c DNA, and then the expression of 4 inflammation-related factor genes is analyzed to determine the anti-inflammatory effect.
The experimental data are expressed as Mean ± SD. Carrying out significance difference statistics by adopting independent sample t test; compared with the blank group, # # # # P is less than 0.0001; compared to the model group, P <0.05, P <0.01, P <0.001, P <0.0001. The statistical results are shown in fig. 4-7, DXM in fig. 4-7: dexamethasone, eth.: ethanol, pet et al petroleum ether, eta. ethyl acetate, N-bu et al N-butanol.
As can be seen from the comparison of FIGS. 4-7, the expression level of the cellular inflammatory factors can be significantly increased by LPS, which indicates that LPS can be used as an inflammation inducer in the experimental study. Compared with an LPS model group, dexamethasone, ethanol parts, petroleum ether parts, ethyl acetate parts and n-butanol parts can obviously reduce the expression level of each inflammatory factor and show obvious anti-inflammatory action. The down regulation effect of the ethanol part, the petroleum ether part and the ethyl acetate part on iNOS, IL-6 and COX-2 is obviously better than that of the n-butanol part, and even partial result is better than that of dexamethasone. Therefore, the ethanol part, the petroleum ether part and the ethyl acetate part are selected as the functional components of the cosmetics with the anti-allergic and relieving effects, and the petroleum ether part and the ethyl acetate part are more preferably selected as the functional components of the cosmetics with the anti-allergic and relieving effects.
Cosmetic test
The petroleum ether fraction, ethanol fraction, ethyl acetate fraction and other components obtained in examples 1 to 3 were prepared into cosmetics, as shown in tables 1 to 3, respectively.
TABLE 1
TABLE 2
TABLE 3
Studies on the inhibitory effects of the cosmetics of tables 1-3 on TNF-alpha inflammatory factor
The compositions of examples 1-3 were assayed for the in vitro TNF- α inflammatory factor content according to the standard T/SHRH 034-2021 test for soothing efficacy of cosmetics, determination of the content of in vitro TNF- α inflammatory factor, lipopolysaccharide-induced macrophage RAW264.7 test method.
The experimental method comprises the following steps:
(1) cell preparation: thawing the cells at 1X 10 5 cell·mL -1 Cell concentration in 96-well plates, 37 ℃,5% CO 2 Culturing in an incubator for 24 hours to ensure that the fusion degree reaches 45-60 percent;
(2) preparing a test object: dissolving the test substance in DMSO, mixing well to ensure that the concentration of folium Hibisci Mutabilis is 200 μ g/mL -1 LPS concentration was 1. Mu.g/mL -1 Dexamethasone concentration 100. Mu.g/mL -1 ；
(3) Cell digestion and inoculation: cells were digested with trypsin/EDTA at a cell concentration of 1X 10 5 cell·mL -1 Inoculating into a 96-well plate at a liquid volume of 200. Mu.L/well, and culturingCulturing in a box for 24 hours;
(4) induction and administration: discarding the culture medium in a 96-well plate, adding a cell culture medium containing LPS into a negative control well according to the experimental design, adding a culture medium containing dexamethasone and LPS into a positive control well, adding a cell culture medium into a blank control well, adding a cosmetic test object into a sample group, and adding 200 mu L of the cosmetic test object into each well. Culturing in an incubator for 24h after the administration is finished;
(5) collecting cell supernatants: after the incubation culture is finished, 200. Mu.L of cell culture supernatant is collected and placed in a 1.5mL sterile centrifuge tube, and the cell culture supernatant is frozen and stored in an ultra-low temperature refrigerator at minus 80 ℃.
(6) And (3) ELISA detection: detection was performed according to the instructions for the TNF-. Alpha.ELISA kit.
The detection results are shown in fig. 8, and it can be seen from fig. 8 that compared with the LPS model group, each test substance has a significant inhibitory effect on TNF- α, and meets the requirements of T/SHRH 034-2021 "cosmetic soothing efficacy test-lipopolysaccharide-induced macrophage RAW264.7 test method for measuring the content of in vitro TNF- α inflammatory factor" standard on cosmetics with soothing efficacy.
Studies on antiallergic efficacy of the cosmetics of tables 1 to 3 are now presented
The test method comprises the following steps: 200 volunteers were screened for skin disease at age 22-45 years and signed an informed consent. The random average was divided into four groups A, B, C and D, 50 of which had no statistical difference among the groups. Group A is blank control group, group B is model group, group C is dexamethasone group, and group D is cosmetic experimental group shown in Table 1. During the test, 5.0% capsaicin was applied to the arms of the three groups B, C and D to cause red swelling and itching of the skin. The B group was not subjected to the subsequent treatment, and the C and D groups were sprayed with the corresponding substances 1 time each within 1 hour. After 1 hour, the regression of symptoms was measured with a multifunctional skin tester. The results are shown in fig. 9, and it can be seen from fig. 9 that the group a does not have any symptoms, all the volunteers in the group B have skin allergy symptoms, and the symptoms of the volunteers in the groups C and D are improved, but the red swelling and itching symptoms are improved more obviously and reduced by 67% after the cosmetic is sprayed for 1 hour, which indicates that the cosmetic containing petroleum ether parts of cotton rose can effectively relieve the allergy symptoms caused by capsaicin.
In conclusion, the invention breaks through the research that the prior art is basically limited to how to extract the cotton rose hibiscus and the antioxidant activity of the extracted cotton rose hibiscus, and does not relate to the research on the specific effective parts corresponding to the allergy-relieving efficacy of the cotton rose hibiscus, namely does not relate to the mode of extracting the cotton rose hibiscus to obtain the cotton rose hibiscus extracting solution with good allergy-relieving effect.
The extracts (namely different solvent parts) obtained by extracting the components in the cotton rose hibiscus by adopting different solvents have great difference in the aspect of allergy relieving, wherein the petroleum ether part, the ethanol part and the ethyl acetate part have obvious allergy relieving effects, and the petroleum ether part and the ethyl acetate part have more obvious effects. The content of the petroleum ether part and the ethyl acetate part in the cosmetics or the food is controlled, so that the cosmetic or the food has no side effect on users, and different products can be prepared for the users to select, thereby being worth popularizing and using.
The above-mentioned embodiments are intended to illustrate the objects, technical solutions and advantages of the present invention in further detail, and it should be understood that the above-mentioned embodiments are merely exemplary embodiments of the present invention, and are not intended to limit the scope of the present invention, and any modifications, equivalent substitutions, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (10)
1. A hibiscus mutabilis extract with a allergy-relieving effect is characterized in that the hibiscus mutabilis extract is derived from at least one of petroleum ether fraction, ethanol fraction and ethyl acetate fraction of hibiscus mutabilis.
2. The hibiscus manihot extract with a allergy-relieving effect according to claim 1, wherein the hibiscus manihot extract is derived from petroleum ether fraction and/or ethyl acetate fraction of hibiscus manihot.
3. A skin allergy-relieving cosmetic comprising the Hibiscus Mutabilis extract of claim 1 or 2; preferably, the content of the hibiscus manihot extract is 0.05-20 wt%, more preferably, 0.2-1 wt%.
4. The skin allergy relieving cosmetic composition of claim 3, wherein the allergy relieving cosmetic composition has a formulation selected from the group consisting of a solution, a topical ointment, a cream, a foam, a nourishing lotion, a moisturizing lotion, a mask, a softening lotion, an emulsion, a makeup base, an essence, a soap, a liquid cleansing product, a bath agent, a sunscreen, a suntan oil, a suspension, an emulsion, a paste, a gel, a face cream, a powder, a soap, a surfactant-containing facial cleanser, an oil, a powder foundation, an emulsion foundation, a cream foundation, a patch, or a spray.
5. The skin soothing cosmetic of claim 4, further comprising one or more cosmetically acceptable carriers.
6. A skin allergy-relieving food comprising the extract of Hibiscus Mutabilis of claim 1 or 2; preferably, the content of the hibiscus manihot extract is 0.05-20 wt%, more preferably, 0.2-1 wt%.
7. The skin allergy free food as claimed in claim 6, wherein the skin allergy free food is a health food.
8. A medical external preparation for skin allergy relief, comprising the hibiscus mutabilis extract of claim 1 or 2, preferably, the hibiscus mutabilis extract is contained in an amount of 0.05 to 20wt%, more preferably, 0.2 to 1wt%.
9. Use of hibiscus mutabilis extract according to claim 1 or 2 in a substance for reducing the content of TNF- α.
10. The use according to claim 9, wherein the substance reducing the TNF- α content is a cosmetic, a medical external or a food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211468125.8A CN115887321A (en) | 2022-11-22 | 2022-11-22 | Hibiscus manihot extract with allergy relieving effect and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211468125.8A CN115887321A (en) | 2022-11-22 | 2022-11-22 | Hibiscus manihot extract with allergy relieving effect and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115887321A true CN115887321A (en) | 2023-04-04 |
Family
ID=86478205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211468125.8A Pending CN115887321A (en) | 2022-11-22 | 2022-11-22 | Hibiscus manihot extract with allergy relieving effect and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115887321A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116693712A (en) * | 2023-06-09 | 2023-09-05 | 成都市中草药研究所(成都市卫生计生药械科技服务中心) | Hibiscus sabdariffa leaf polysaccharide crude extract, and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1292286A (en) * | 1999-09-23 | 2001-04-25 | 上海第二医科大学附属瑞金医院 | Medicine preparation containing cotton rose leaf extract |
| CN101487141A (en) * | 2009-02-23 | 2009-07-22 | 中国科学院过程工程研究所 | Method for producing textile fibre, medicine intermediate and other products from cotton rose hibiscus |
| CN101716199A (en) * | 2009-12-31 | 2010-06-02 | 浙江工业大学 | Method for extracting flavonoids from leaves of cotton rose hibiscus |
| KR20140127525A (en) * | 2013-04-25 | 2014-11-04 | 코스맥스 주식회사 | Compositions for enhancing skin barrier and reducing skin stimulus comprising mixture extract of Hibiscus mutabilis L. and Patrinia villosa Juss. |
| CN104434621A (en) * | 2014-10-30 | 2015-03-25 | 惠州出入境检验检疫局检验检疫综合技术中心 | Antipyrotic and antiallergic traditional Chinese medicine composition and application thereof in preparation of skin care products |
| CN110613739A (en) * | 2019-07-31 | 2019-12-27 | 湖州耕香生物科技有限公司 | Method for separating flavonoid compounds in cotton rose based on high-speed countercurrent chromatography |
| CN110638848A (en) * | 2019-08-16 | 2020-01-03 | 湖州耕香生物科技有限公司 | Method for extracting effective components from folium Hibisci Mutabilis based on transdermal absorption technology |
| CN112545948A (en) * | 2021-01-13 | 2021-03-26 | 李冬梅 | Natural plant extract composition and application thereof in cosmetics |
-
2022
- 2022-11-22 CN CN202211468125.8A patent/CN115887321A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1292286A (en) * | 1999-09-23 | 2001-04-25 | 上海第二医科大学附属瑞金医院 | Medicine preparation containing cotton rose leaf extract |
| CN101487141A (en) * | 2009-02-23 | 2009-07-22 | 中国科学院过程工程研究所 | Method for producing textile fibre, medicine intermediate and other products from cotton rose hibiscus |
| CN101716199A (en) * | 2009-12-31 | 2010-06-02 | 浙江工业大学 | Method for extracting flavonoids from leaves of cotton rose hibiscus |
| KR20140127525A (en) * | 2013-04-25 | 2014-11-04 | 코스맥스 주식회사 | Compositions for enhancing skin barrier and reducing skin stimulus comprising mixture extract of Hibiscus mutabilis L. and Patrinia villosa Juss. |
| CN104434621A (en) * | 2014-10-30 | 2015-03-25 | 惠州出入境检验检疫局检验检疫综合技术中心 | Antipyrotic and antiallergic traditional Chinese medicine composition and application thereof in preparation of skin care products |
| CN110613739A (en) * | 2019-07-31 | 2019-12-27 | 湖州耕香生物科技有限公司 | Method for separating flavonoid compounds in cotton rose based on high-speed countercurrent chromatography |
| CN110638848A (en) * | 2019-08-16 | 2020-01-03 | 湖州耕香生物科技有限公司 | Method for extracting effective components from folium Hibisci Mutabilis based on transdermal absorption technology |
| CN112545948A (en) * | 2021-01-13 | 2021-03-26 | 李冬梅 | Natural plant extract composition and application thereof in cosmetics |
Non-Patent Citations (5)
| Title |
|---|
| 吴力超等: ""基于网络药理学和细胞实验探讨豆甾醇抗炎作用"", 《中成药》, vol. 44, no. 2, 28 February 2022 (2022-02-28), pages 1 - 7 * |
| 张小芬: ""芙蓉叶中化学成分的研究"", 《全国优秀硕士论文集》, no. 12, 15 December 2021 (2021-12-15), pages 1 - 121 * |
| 杨杰: ""芦丁的体外抗炎作用及机制研究"", 《全国优秀硕士论文集》, no. 3, 15 March 2021 (2021-03-15), pages 1 - 69 * |
| 汪本学等: "《浙江农业文化遗产调查研究》", 30 June 2018, 上海交通大学出版社, pages: 321 * |
| 王艺等: ""UPLC-Q-Orbitrap HRMS技术快速鉴定木芙蓉花化学成分"", 《天然产物研究与开发》, no. 33, 30 November 2021 (2021-11-30), pages 2042 - 2052 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116693712A (en) * | 2023-06-09 | 2023-09-05 | 成都市中草药研究所(成都市卫生计生药械科技服务中心) | Hibiscus sabdariffa leaf polysaccharide crude extract, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102207995B1 (en) | Composition for Anti-microbial, Anti-inflammation, and Skin Hydration Property Comprising Fermented Extract of Momordica charantia as Active Ingredient | |
| KR102348042B1 (en) | Composition for improving skin condition comprising extract of hydrangea serrata | |
| CN113694115A (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
| KR20150086982A (en) | Composition comprising Polygala tenuifolia extract for preventing or treating atopic dermatitis | |
| KR20200097673A (en) | Composition for improving skin troubles comprising mortierella oil as an active ingredient | |
| KR101698922B1 (en) | Composition for promoting hair growth and restoration | |
| JP2005213178A (en) | TNF-alpha PRODUCTION INHIBITOR, ESTROGENIC AGENT AND EXTERNAL PREPARATION FOR SKIN | |
| CN115887321A (en) | Hibiscus manihot extract with allergy relieving effect and application thereof | |
| WO2011043212A1 (en) | Ceramide production enhancer and moisturizing agent | |
| KR20090084435A (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of houttuynia cordata thub and ulmus davidana var.japonica as an active ingredient | |
| KR102241951B1 (en) | Composition for preventing, treating or improving prostate disease or alopecia comprising mixed extracts of Angelica gigas and Torilis japonica | |
| US20240115642A1 (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as an active ingredient | |
| KR101705354B1 (en) | A composition comprising the alcohol extract of Botrychium ternatum for preventing or treating skin inflammation | |
| CN104644494A (en) | Composition Containing Natural Plant Extracts As Effective Constituents, External Skin Preparation Comprising The Same, Cosmetic Preparation Comprising The Same And Pharmaceutical Preparation Comprising The Same | |
| JP5004529B2 (en) | Histamine release inhibitor | |
| KR102577528B1 (en) | Composition for improving skin | |
| KR102017002B1 (en) | Anti-atopic composition comprising extract of Geomgangsong thinning by-product as effective component | |
| KR102144566B1 (en) | A composition for preventing or terating atopic dermatitis comprising lycopi herba extract as an active ingredient | |
| KR20180055137A (en) | Composition comprising Rhus Semialata extract as active ingredient | |
| KR102058022B1 (en) | Composition for antioxidant and anti-inflammatory comprising fraction of Ledum palustre L. extract as effective component | |
| KR20220096277A (en) | Composition for Preventing or Treating Hair Loss or Stimulating Hair Sprouting or Hair Growth Comprising Extracts of Rosa davurica Pall as Active Ingredient | |
| KR101897720B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth comprising Tenebrio molitor fractions | |
| KR102513248B1 (en) | Composition comprising undaria pinnatifida sporophyll extract treated with pulsed electric field | |
| KR102519671B1 (en) | Acne cosmetic composition, and manufacturing method thereof | |
| KR102513966B1 (en) | Cosmetic composition for anti-inflammatory and skin surpression comprising nanoliposome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |